U.S. markets closed

Apellis Pharmaceuticals, Inc. (APLS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
49.81-2.68 (-5.11%)
At close: 4:00PM EST

49.81 0.00 (0.00%)
After hours: 4:30PM EST

Show:
Income Statement
Balance Sheet
Cash Flow
Annual
Subscribe to Premium to download historical data

Income Statement

All numbers in thousands
Get access to 40+ years of historical data with Yahoo Finance Premium.Learn more
Breakdown
ttm
12/31/2019
12/31/2018
12/31/2017
Total Revenue
0
0
0
0
Operating Expense
338,150
288,015
127,925
50,767
Operating Income
-338,150
-288,015
-127,925
-50,767
Net Non Operating Interest Income Expense
-2,094
-175.831
447.815
-96.915
Other Income Expense
-82,711
-16,516
-25.249
-142.15
Pretax Income
-422,955
-304,707
-127,502
-51,006
Net Income Common Stockholders
-422,955
-304,707
-127,502
-51,006
Diluted NI Available to Com Stockholders
-422,955
-304,707
-127,502
-51,006
Basic EPS
-
-0.0049
-0.0023
-0.0037
Diluted EPS
-
-0.0049
-0.0023
-0.0037
Basic Average Shares
-
62,229
54,396
13,871
Diluted Average Shares
-
62,229
54,396
13,871
Total Operating Income as Reported
-338,150
-288,015
-127,925
-50,767
Total Expenses
338,150
288,015
127,925
50,767
Net Income from Continuing & Discontinued Operation
-422,955
-304,707
-127,502
-51,006
Normalized Income
-340,152
-288,366
-127,588
-50,852
Interest Income
6,517
5,109
2,961
-
Interest Expense
8,611
5,285
2,513
-
Net Interest Income
-2,094
-175.831
447.815
-96.915
EBIT
-414,344
-299,422
-124,989
-50,767
EBITDA
-414,076
-
-
-
Reconciled Depreciation
267.683
239.683
-
11.935
Net Income from Continuing Operation Net Minority Interest
-422,955
-304,707
-127,502
-51,006
Total Unusual Items Excluding Goodwill
-82,802
-16,340
85.509
-153.692
Total Unusual Items
-82,802
-16,340
85.509
-153.692
Normalized EBITDA
-331,274
-282,842
-125,075
-50,601
Tax Rate for Calcs
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0